{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:32:21Z","timestamp":1788546741088,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"37","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA9685-29"],"award-info":[{"award-number":["T32 CA9685-29"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 249663-A1"],"award-info":[{"award-number":["CA 249663-A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA 249663-A1"],"award-info":[{"award-number":["CA 249663-A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2024,9,6]]},"DOI":"10.1038\/s41388-024-03095-0","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T13:01:54Z","timestamp":1723813314000},"page":"2806-2819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors"],"prefix":"10.1038","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1174-3307","authenticated-orcid":false,"given":"Aradhya","family":"Nigam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5435","authenticated-orcid":false,"given":"Gnana P.","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid K.","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Saqcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandakini","family":"Venkatramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-4904","authenticated-orcid":false,"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-2517","authenticated-orcid":false,"given":"James A.","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"3095_CR1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80:2969\u201374.","journal-title":"Cancer Res"},{"key":"3095_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287\u201392.","journal-title":"J Cell Sci"},{"key":"3095_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"3095_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","volume":"14","author":"K Chen","year":"2021","unstructured":"Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol. 2021;14:116.","journal-title":"J Hematol Oncol"},{"key":"3095_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.03.001","volume":"54","author":"AQ Khan","year":"2019","unstructured":"Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA, et al. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol. 2019;54:1\u201313.","journal-title":"Semin Cancer Biol"},{"key":"3095_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"3095_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jb\/mvv060","volume":"158","author":"F Shima","year":"2015","unstructured":"Shima F, Matsumoto S, Yoshikawa Y, Kawamura T, Isa M, Kataoka T. Current status of the development of Ras inhibitors. J Biochem. 2015;158:91\u20139.","journal-title":"J Biochem"},{"key":"3095_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401:733\u201346.","journal-title":"Lancet"},{"key":"3095_CR9","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl J Med. 2021;384:2371\u201381.","journal-title":"N. Engl J Med"},{"key":"3095_CR10","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","volume":"78","author":"BR Untch","year":"2018","unstructured":"Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, et al. Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers. Cancer Res. 2018;78:4642\u201357.","journal-title":"Cancer Res"},{"key":"3095_CR11","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","volume":"19","author":"M Gilardi","year":"2020","unstructured":"Gilardi M, Wang Z, Proietto M, Chilla A, Calleja-Valera JL, Goto Y, et al. Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas. Mol Cancer Ther. 2020;19:1784\u201396.","journal-title":"Mol Cancer Ther"},{"key":"3095_CR12","doi-asserted-by":"crossref","unstructured":"Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, et al. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. 2022;41:2973\u201383.","DOI":"10.1038\/s41388-022-02305-x"},{"key":"3095_CR13","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.2174\/09298673113206660262","volume":"20","author":"NS Moorthy","year":"2013","unstructured":"Moorthy NS, Sousa SF, Ramos MJ, Fernandes PA. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. Curr Med Chem. 2013;20:4888\u2013923.","journal-title":"Curr Med Chem"},{"key":"3095_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","volume":"10","author":"NM Appels","year":"2005","unstructured":"Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10:565\u201378.","journal-title":"Oncologist"},{"key":"3095_CR15","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459\u201364.","journal-title":"J Biol Chem"},{"key":"3095_CR16","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.20.02903","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39:1856\u201364.","journal-title":"J Clin Oncol"},{"key":"3095_CR17","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020;126:3972\u201381.","journal-title":"Cancer"},{"key":"3095_CR18","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-20-1246","volume":"26","author":"HW Lee","year":"2020","unstructured":"Lee HW, Sa JK, Gualberto A, Scholz C, Sung HH, Jeong BC, et al. A phase II trial of tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations. Clin Cancer Res. 2020;26:5113\u20139.","journal-title":"Clin Cancer Res"},{"key":"3095_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-1-0716-1190-6_21","volume":"2262","author":"CG Lechuga","year":"2021","unstructured":"Lechuga CG, Salmon M, Paniagua G, Guerra C, Barbacid M, Drosten M. RASless MEFs as a tool to study RAS-dependent and RAS-independent functions. Methods Mol Biol. 2021;2262:335\u201346.","journal-title":"Methods Mol Biol"},{"key":"3095_CR20","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/onc.2012.404","volume":"32","author":"MD To","year":"2013","unstructured":"To MD, Rosario RD, Westcott PM, Banta KL, Balmain A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene. 2013;32:4028\u201333.","journal-title":"Oncogene"},{"key":"3095_CR21","doi-asserted-by":"crossref","unstructured":"Sheffels E, Kortum RL. The role of wild-type RAS in oncogenic RAS transformation. Genes. 2021;12:662.","DOI":"10.3390\/genes12050662"},{"key":"3095_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/1389557515666151001152212","volume":"16","author":"M Chen","year":"2016","unstructured":"Chen M, Peters A, Huang T, Nan X. Ras dimer formation as a new signaling mechanism and potential cancer therapeutic target. Mini Rev Med Chem. 2016;16:391\u2013403.","journal-title":"Mini Rev Med Chem"},{"key":"3095_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcdb.2016.07.012","volume":"58","author":"B Zhou","year":"2016","unstructured":"Zhou B, Der CJ, Cox AD. The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol. 2016;58:60\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"3095_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cell.2017.12.020","volume":"172","author":"C Ambrogio","year":"2018","unstructured":"Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, et al. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell. 2018;172:857\u201368.e15.","journal-title":"Cell"},{"key":"3095_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nchembio.2231","volume":"13","author":"R Spencer-Smith","year":"2017","unstructured":"Spencer-Smith R, Koide A, Zhou Y, Eguchi RR, Sha F, Gajwani P, et al. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol. 2017;13:62\u20138.","journal-title":"Nat Chem Biol"},{"key":"3095_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/onc.2017.391","volume":"37","author":"P Dietrich","year":"2018","unstructured":"Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. Oncogene. 2018;37:897\u2013911.","journal-title":"Oncogene"},{"key":"3095_CR27","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","volume":"24","author":"M Bahcall","year":"2018","unstructured":"Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, et al. Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clin Cancer Res. 2018;24:5963\u201376.","journal-title":"Clin Cancer Res"},{"key":"3095_CR28","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin Cancer Res. 2020;26:1633\u201343.","journal-title":"Clin Cancer Res"},{"key":"3095_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-4060","volume":"26","author":"R Yaeger","year":"2020","unstructured":"Yaeger R, Solit DB. Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting. Clin Cancer Res. 2020;26:1538\u201340.","journal-title":"Clin Cancer Res"},{"key":"3095_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","volume":"24","author":"GS Wong","year":"2018","unstructured":"Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24:968\u201377.","journal-title":"Nat Med"},{"key":"3095_CR31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 2020;10:1129\u201339.","journal-title":"Cancer Discov"},{"key":"3095_CR32","doi-asserted-by":"publisher","first-page":"12981","DOI":"10.1074\/jbc.M117.778886","volume":"292","author":"CW Johnson","year":"2017","unstructured":"Johnson CW, Reid D, Parker JA, Salter S, Knihtila R, Kuzmic P, et al. The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects. J Biol Chem. 2017;292:12981\u201393.","journal-title":"J Biol Chem"},{"key":"3095_CR33","doi-asserted-by":"publisher","first-page":"17164","DOI":"10.1074\/jbc.274.24.17164","volume":"274","author":"JK Voice","year":"1999","unstructured":"Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 1999;274:17164\u201370.","journal-title":"J Biol Chem"},{"key":"3095_CR34","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-08-0086","volume":"14","author":"C Mussi","year":"2008","unstructured":"Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res. 2008;14:4550\u20135.","journal-title":"Clin Cancer Res"},{"key":"3095_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2019.05.013","volume":"36","author":"A Woolston","year":"2019","unstructured":"Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. Cancer Cell. 2019;36:35\u201350.e9.","journal-title":"Cancer Cell"},{"key":"3095_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427\u201338.e6.","journal-title":"Cancer Cell"},{"key":"3095_CR37","doi-asserted-by":"crossref","unstructured":"Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, et al. BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: the need for a new pre-clinical treatment rationale. Cancers. 2019;11:1381.","DOI":"10.3390\/cancers11091381"},{"key":"3095_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234\u20138.","journal-title":"Nature"},{"key":"3095_CR39","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183\u201399.","journal-title":"Oncogene"},{"key":"3095_CR40","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl J Med. 2021;384:2382\u201393.","journal-title":"N. Engl J Med"},{"key":"3095_CR41","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1073\/pnas.1523693113","volume":"113","author":"SH Ebbesen","year":"2016","unstructured":"Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, et al. Pten loss promotes MAPK pathway dependency in HER2\/neu breast carcinomas. Proc Natl Acad Sci USA. 2016;113:3030\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3095_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251\u201364.","journal-title":"J Mol Diagn"},{"key":"3095_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"The AACR Project GENIE Consortium.","year":"2017","unstructured":"The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331.","journal-title":"Cancer Discov"},{"key":"3095_CR44","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011."},{"key":"3095_CR45","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131.","journal-title":"Nucleic Acids Res"},{"key":"3095_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29:1091\u2013104.","journal-title":"EMBO J"},{"key":"3095_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","volume":"3","author":"C Montero-Conde","year":"2013","unstructured":"Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3:520\u201333.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03095-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03095-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03095-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T05:03:07Z","timestamp":1725598987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03095-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":47,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2024,9,6]]}},"alternative-id":["3095"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03095-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3154719\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAF and BRU hold patent reference SK 2014-024-03 (title: Treatment of H-RAS-driven tumors; application number: 15\/305,788).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}